ReviewHuman vaccines2011
Schistosomiasis vaccines.
Review in Human vaccines, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed.
- Potential biomarker and composite efficacy readout for human clinical trials of schistosomiasis vaccine in Africa.Scientific reports · 2025Article
- Evaluation of schistosomula lung antigen preparation and soluble egg antigen vaccines on experimental schistosomiasis mansoni.Parasites, hosts and diseases · 2023Article
- Effects of Structurally Different HDAC Inhibitors againstACS infectious diseases · 2022Article
- Whole-Proteome Differential Screening Identifies Novel Vaccine Candidates for Schistosomiasis japonica.The Journal of infectious diseases · 2021Article
- Current status and future prospects of protein vaccine candidates againstParasite epidemiology and control · 2020Review
- Review
- Article
- Schistosomiasis-from immunopathology to vaccines.Seminars in immunopathology · 2020Review
- Current and Novel Therapies Against Helminthic Infections: The Potential of Antioxidants Combined with Drugs.Biomolecules · 2020Review
- Investigating Immunization With Nucleotide Enzymes ofFrontiers in immunology · 2020Article
- Analysis of the interactome of Schistosoma mansoni histone deacetylase 8.PLoS neglected tropical diseases · 2017Article
- Sm-p80-Based Schistosomiasis Vaccine: Preparation for Human Clinical Trials.Trends in parasitology · 2017Review
- A Rare Case of Schistosomiasis (Bilharzia) of the Bladder in a Non-Endemic Area.Polish journal of radiology · 2017Article
- Schistosomiasis vaccines: where do we stand?Parasites & vectors · 2016Review
- Experiences and perspectives of community health workers from implementing treatment for schistosomiasis using the community directed intervention strategy in an informal settlement in Kisumu City, western Kenya.BMC public health · 2016Article
- Development of a schistosomiasis vaccine.Expert review of vaccines · 2016Review
- Eliminating the Neglected Tropical Diseases: Translational Science and New Technologies.PLoS neglected tropical diseases · 2016Review
- What is required in terms of mass drug administration to interrupt the transmission of schistosome parasites in regions of endemic infection?Parasites & vectors · 2015Article
- In Vivo MRI Assessment of Hepatic and Splenic Disease in a Murine Model of Schistosomiasis [corrected].PLoS neglected tropical diseases · 2015Article
- It's All about Those Bases: The Need for Incorporating Parasite Genetic Heterogeneity into the Development of Schistosome Vaccines.PLoS neglected tropical diseases · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Schistosomiasis is a major neglected tropical disease of public health importance to a billion people. An estimated 200 million people are currently infected; an additional 779 million individuals are at risk to acquire the infection in 74 countries. Despite many years of implementation of mass anti-parasitic drug therapy programs and other control measures, this disease has not been contained and continues to spread to new geographic areas. The discovery of a protective vaccine still remains the most potentially effective means for the control of this disease, especially if the vaccine provides long-term immunity against the infection. A vaccine would contribute to the reduction of schistosomiasis morbidity through induced immune responses leading to decrease in parasite load and reduced egg production. This vaccine could be administered to children between the ages of 3 and 12 years to prevent severe infection in a particularly high risk population. This review summarizes the current status of schistosomiasis vaccine development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.